During embryologic development, the fetus contains both mesonephric (Wolffian) and paramesonephric (Mullerian) ducts. In a 46, XY male, the SRY gene on the Y chromosome produces testis-determining factor, which leads to the development of the testes. The testes are made of two compartments: seminiferous tubules, which enclose Sertoli cells, and interstitial tissue, which house Leydig cells 4. Sertoli cells secrete anti-Mullerian hormone (AMH), also known as Mullerian inhibiting substance or factor, which suppresses the development of paramesonephric ducts, thereby inhibiting the formation of female internal structures, notably the uterus, fallopian tubes, and proximal vagina. Leydig cells secrete androgens that stimulate the development of mesonephric ducts, leading to the formation of male internal structures, including the seminal vesicles, epididymis, ejaculatory duct, and vas deferens. Androgens are converted to dihydrotestosterone to allow the urogenital sinus and genital tubercle to form the prostate and male external genitalia, respectively 5.
Female phenotype is the default phenotype, where even a 46, XY male will develop internal female structures if he has a defective SRY gene, Sertoli cells that fail to produce functional AMH, or have defective type II AMH receptors (AMH-IIR) 6. In all, 85% of PMDS cases are due to a nonfunctional mutation in AMH or AMH-IIR gene that has autosomal recessive transmission. The remaining 15% of cases are idiopathic 7.
PMDS is typically discovered incidentally during an inguinal hernia repair or orchiopexy. Clinically, patients have normal growth and development without any external deficiencies. Upon identification, PMDS is divided into classes: class A (60–70%) – bilateral undescended testicles embedded in the broad ligament located in the area analogous to ovaries in a female; class B (20–30%) – unilateral undescended testicle with ipsilateral inguinal hernia that may contain the testis, uterus, and fallopian tubes (i.e. hernia uteri inguinale); and class C (10%) – involves transverse testicular ectopia with both testes in the same hernia sac along with Mullerian structures 8.
Management of the patient with PMDS is still under discussion. Depending on the age of diagnosis, orchiopexy or orchiectomy should be performed to help preserve fertility or eliminate the possibility of testicular malignancies, respectively. With regard to Mullerian structures, initially nonoperative management was favored because of difficulty in identifying the vas deferens, as many times it is found intimately adherent to lateral walls of the uterus or the fallopian tubes, and risk of damage to the vas deferens and testicular vesicles may lead to infertility and significant morbidity. In addition, it was believed that retention of Mullerian remnants was low risk 1. However, 11 cases of advanced malignancies stemming from these remnants, even in the pediatric population, have been identified, many of which within the past two decades 2,8. Furthermore, patients with PMDS are at a greater risk for Mullerian malignancy than testicular malignancy, resulting in increasing support for surgical intervention 9,10.
The majority of interventions have been staged, with stage 1 involving gonadal biopsy and hernia repair and stage 2 addressing the testes and Mullerian remnants. Of note, Manjunath et al.8 argue that if the epididymis and vas deferens are present, this would unequivocally reveal that the gonads are testes, and a staged procedure is not needed as orchiopexy can be performed during initial exploration. This would eliminate the need for a biopsy and prevents insult to the blood–testes barrier and the possibility of forming antisperm antibodies, which would further decrease fertility 11. Guerrier et al. 12 advocate bilateral proximal salpingectomies, leaving fimbriae with the epididymis, hysterectomy, and bilateral orchiopexy, if the testes are normal. If the testes are atrophic, orchiectomy should be performed. Risk of testicular malignancy in patients with PMDS is 5–18%, similar to that of patients with cryptorchidism 2. Many patients present with neglected cryptorchidism (mean age 8.2 years in one study) and have short spermatic vessels, necessitating a staged Fowler–Stephens orchiopexy (FSO) 2. However, dissection of Mullerian remnants would significantly risk damage to the deferential vessels, the remaining blood supply to the testes. Because of greater likelihood of testicular atrophy if FSO and Mullerian remnant excision are being done together, Shalaby et al.2 advocate for leaving the Mullerian remnants in place whenever FSO is necessary and opt for long-term follow-up. Manjunath et al.8 advocate for removal of remnants that can be safely removed, without risking damage to the vas deferens or testicular blood supply, and stripping/destroying the mucosa of the retained Mullerian remnants to reduce the risk of malignancy, which originate from the mucosa. Subsequently demonstrating that in patients where FSO is necessary, a midline splitting of the Mullerian remnants with obliteration of mucosa would allow for complete mobilization of both testes without risking damage to the vas deferens or testicular blood supply 8.
The treatment plan for our patient is to perform laparoscopic total abdominal hysterectomy with bilateral proximal salpingectomy and bilateral orchiopexy.
Author would like to thank Palestinian Children’s Relief Fund and Al-Shifa Hospital in Gaza, Palestine for their continued dedication and commitment to serving the children in Palestine and for allowing us to partake in their care and education.
Conflicts of interest
There are no conflicts of interest.
1. Ahdoot M, Qadan M, Santa-Maria M, Kennedy WA, Ilano A. Indirect inguinal hernia with uterine tissue in a male: a case of persistent Mullerian duct syndrome and literature review. Can Urol Assoc J 2013; 7:E121–E124.
2. Shalaby MM, Kurkar A, Zarzour MA, Faddan AA, Khalil M, Abdelhafez MF. The management of the persistent Müllerian duct syndrome. Arab J Urol 2014; 12:239–244.
3. Odi T, Abdur-Rahman L, Nasir A. Persistent Mullerian duct syndrome: a case report and review of the literature. Afr J Paediatr Surg 2010; 7:191.
4. Grinspon RP, Rey RA. Anti-Müllerian hormone and sertoli cell function in paediatric male hypogonadism. Horm Res Paediatr 2010; 73:81–92.
5. Josso N. Biology and genetics of anti-Müllerian hormone. Adv Exp Med Biol 2011; 25:83–85.
6. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab 2011; 25:221–238.
7. Josso N, Rey RA, Picard JY. Anti-Müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. Int J Endocrinol 2013; 2013:674105.
8. Manjunath BG, Shenoy VG, Raj P. Persistent Müllerian duct syndrome: how to deal with the Müllerian duct remnants – a review. Indian J Surg 2010; 72:16–19.
9. Farikullah J, Ehtisham S, Nappo S, Patel L, Hennayake S. Persistent Müllerian duct syndrome: lessons learned from managing a series of eight patients over a 10-year period and review of literature regarding malignant risk from the Müllerian remnants. BJU Int 2012; 110 (Pt C):E1084–E1089.
10. Le Cornet C, Lortet-Tieulent J, Forman D, Béranger R, Flechon A, Fervers B, et al. Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. Eur J Cancer 2014; 50:831–839.
11. Francavilla F, Santucci R, Barbonetti A, Francavilla S. Naturally-occurring antisperm antibodies in men: interference with fertility and clinical implications. An update. Front Biosci 2007; 12:2890–2911.
© 2018 Annals of Pediatric Surgery
12. Guerrier D, Tran D, Vanderwinden JM, Hideux S, van Outryve L, Legeai L, et al. The persistent Müllerian duct syndrome: a molecular approach. J Clin Endocrinol Metab 1989; 68:46–52.